Click on image to view larger version.

Figure 3 Adjusted and Unadjusted In-Hospital Outcomes of Patients Treated With Abciximab Versus Eptifibatide

The first plot (left) shows unadjusted odds ratios, the second plot (center) shows risk-adjusted odds ratios, and the third plot (right) shows risk-adjusted and propensity-adjusted odds ratios. There was no difference in major cardiovascular complications between patients treated with abciximab and eptifibatide. Contrast nephropathy and gastrointestinal bleeding were more common in patients treated with abciximab, but this difference was not significant after risk adjustment or after adjusting for the propensity to receive abciximab. CABG = coronary artery bypass grafting; MACE = major adverse cardiac events.